Table 4.
Base case cost-effectiveness results (per patient) estimated over lifetime
| Component | ACEI | Sacubitril/valsartan | Incremental | ||||||
| UK (GBP) | Denmark (DKK) | Colombia (COP) | UK (GBP) | Denmark (DKK) | Colombia (COP) | UK (GBP) | Denmark (DKK) | Colombia (COP) | |
| Primary therapy costs | 170 | 1281 | 3 575 530 | 8836 | 89 821 | 21 000 189 | 8665 | 88 540 | 17 424 660 |
| Background therapy costs | 607 | 5729 | 4 138 229 | 662 | 6226 | 4 478 344 | 55 | 497 | 340 116 |
| Hospitalisation costs | 8296 | 132 368 | 17 679 700 | 7697 | 122 267 | 16 273 369 | −598 | −10 102 | −1 406 331 |
| HF management costs | 5639 | 5605 | 3 792 947 | 6153 | 6091 | 4 104 685 | 514 | 486 | 311 737 |
| Adverse events | 102 | 364 | 98 318 | 110 | 393 | 100 044 | 8 | 29 | 1725 |
| Titration | 0 | 0 | 0 | 262 | 1534 | 51 600 | 262 | 1534 | 51 600 |
| Total costs | 14 814 | 145 346 | 29 284 724 | 23 720 | 226 330 | 46 008 231 | 8906 | 80 984 | 16 723 507 |
| QALYs | 5.06 | 4.81 | 4.52 | 5.58 | 5.27 | 4.95 | 0.52 | 0.47 | 0.42 |
| ICER | 17 134 | 173 994 | 39 522 754 | ||||||
ACEI, angiotensin-converting-enzyme inhibitor; COP, Colombian peso; DKK, Danish kroner; GBP, British pound sterling; HF, heart failure; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-years.